Search Results for keywords:"patent term extension"

The United States Patent and Trademark Office (USPTO) has granted a one-year interim extension for U.S. Patent No. 7,534,790, which covers the drug vernakalant hydrochloride. The extension was necessary because the regulatory review by the Food and Drug Administration (FDA) will extend beyond the patent's expiration date of March 31, 2021. Correvio International Sàrl, the patent owner, applied for this third interim extension as allowed under U.S. patent law for certain cases where market approval is pending. This extension ensures the patent remains valid while the review process continues.

The United States Patent and Trademark Office has granted a one-year interim extension for U.S. Patent No. 6,953,476, which belongs to Neovasc Medical Ltd. This patent covers an implantable device called Reducer®, and the extension was needed because the regulatory review by the Food and Drug Administration is expected to take longer than the patent's original expiration date. The extension allows Neovasc more time to prepare while waiting for the FDA's approval process to conclude.